Neoadjuvant and metastatic breast cancer 2024:

Lee Schwartzberg MD, FACP, FACCC Chief, Oncology and Hematology Renown Health-Pennington Cancer Institute Professor of Clinical Medicine University of Nevada, Reno School of Medicine


> Pennington Cancer Institute

Disclosures

- Advisor/Consultant: AstraZeneca, Daiichi Sankyo, Novartis, Spectrum, Napo, Genentech, Foundation Medicine, Coherus, GSK
- Speaker Bureau: AstraZeneca, Merck, Daiichi Sankyo, Novartis




Breast Cancer Incidence 2024



Year of diagnosis

- In situ cancer: 63,000
- Invasive Cancer: 297,000
- Deaths from breast cancer: 43,000
- Lifetime risk 12.6% (one in 8 women)

Figure 6b. Trends in Female Breast Cancer Death Rates by Race/Ethnicity, 1975-2015, US



1991:

50 year old woman with palpable breast mass and axillary LN Imaging: 4 cm mass in Left breast, enlarged I N **Biopsy: Invasive** cancer, NOS, poorly differentiated ER+ PR+ by LBA; HER2 N/A; Ki-67 N/A

Total Mastectomy and axillary lymph node dissection:

Path: 4.2 x 4 cm IDC, 2/18 lymph nodes positive

Doxorubicin based adjuvant chemotherapy

Radiation x 5 weeks including all LNs + 1 week boost to chest wall/scar

Tamoxifen for 5 years

1991 Outcome

EFFICACY

• 30-40% chance of distant recurrence at 10 yrs

TOXICITY

- 35-40% chance of clinical lymphedema
- 10-20% chance of chronic chest wall pain/fibrosis
- 1-5% chance of cardiac disease



Treatment changes over past 30 years

1991

- Mastectomy for large tumors
- Radiation to chest wall and TNI if node +
- Multiagent adjuvant chemotherapy
- Tamoxifen for ER+
- Limited understanding of subtypes

2024

- Treat breast cancer by subtype
- Improved imaging and clip placement preoperatively
- Neoadjuvant chemotherapy for many
- Reduce surgery (partial mast) and radiation based on chemotherapy response
- Biologic and Immunologic therapies for many
- Improved endocrine therapy (Als, OFS)

2024: 50 year old woman with palpable breast mass and LN Imaging: Mammo +US: 3 cm mass in Left breast, enlarged LN, MRI: 4 cm mass, 2.5 cm solitary LN **US Biopsy: Invasive** ductal ca, grade 3, ER+ 80% PR+ 10%; HER2 3+; Ki-67 30%; I N + Clips placed in breast and LN

Neoadjuvant TCHP; Clinical complete response by exam and imaging

Partial Mastectomy + Targeted axillary dissection Path: pCR in breast and lymph nodes

Anti-HER2 Ab adjuvant therapy

Radiation to breast/No additional radiation to LNs

Aromatase inhibitor x 5 years

Outcome change over 30+ years

1991

EFFICACY

30-40% chance of distant recurrence at 10 yrs

TOXICITY

- 35-40% chance of clinical lymphedema
- 10-20% chance of chronic chest wall pain/fibrosis
- 1-5% chance of cardiac disease

2024

EFFICACY


 5-10% chance of distant recurrence at 10 yrs

TOXICITY

- 5-10% chance of clinical lymphedema
- 3-5% chance of chronic chest wall pain/fibrosis
- 1-3% chance of cardiac disease


Breast cancer death rates have decreased 40% in past 30 years...

while interventions have reduced toxicity and side effects



DeSantis, CE et al; CA-A Cancer Journal for Clinicians 2019


Improvements in Breast Cancer Mortality are due to: Improvements in adjuvant therapy, metastatic therapy, and screening



JAMA 2024

2019-2024: Incremental improvement in adjuvant and metastatic treatment

Invasive breast is composed of 3 major subtypes




Immunohistochemistry Standard

- Estrogen receptor (ER)
- Progesterone receptor (PR)
- Human Epidermal growth factor Receptor-2 (HER2)
- Ki-67

Definition of ER/PR status:

- ER-negative: < 1% positive tumor cells
- ER-positive> 10% positive tumor cells
- ER-low: 1-10% positive tumor cells



Pennington Cancer Institute

Increasing the cure rate for breast cancer: Lessons learned

- Early stage have higher cure rate
 - Screening
 - Early detection
- All invasive breast cancers have the potential for distant micromets at diagnosis
 - Adjuvant therapy can cure micrometastatic disease
 - Perioperatively
 - Postoperatively
 - Preoperatively
- Metastatic disease (macrometastatic disease) can be controlled by better therapy
 - Treat by subtype
 - Develop targeted therapy

Why use Neoadjuvant Systemic Therapy?

Traditional

Downstage disease, improve resectability and breast conservation


Reduce extent of axillary surgery

Contemporary

- Risk stratification to guide adjuvant therapy
- Provide long-term prognostic information
- Early assessment of novel agents/combinations

➢Growing

- Response/resistance biomarkers to optimize patient selection for available therapies
- Pathological response-guided escalation and de-escalation clinical trials



Which EBC patients Should Be Considered for Preoperative Systemic Therapy for EBC?

Patients with HER2+ EBC who have a tumor ≥ 2 cm (T2) diameter or who have node-positive disease regardless of hormone receptor status should receive neoadjuvant chemotherapy with the addition of trastuzumab/pertuzumab

Patients with TNBC who have a tumor ≥ 2 cm (T2) diameter or who have node-positive disease should receive neoadjuvant chemotherapy with the addition of pembrolizumab

Patients with HR+HER2- EBC who are high-risk by age, tumor size, nodal status, and grade should consider neoadjuvant chemotherapy

Critical Need: Coordination between the surgeon, medical oncologist and radiologist during neoadjuvant therapy



5 nix

Modern Principles of Neoadjuvant Chemotherapy


- Use the same chemotherapy before as would be used after
- Follow clinical response by examination and imaging
- Stop chemotherapy and proceed to surgery only if progression while on chemotherapy (<5%)
- Response guided chemotherapy for some?
- pCR is a surrogate for better long-term outcome on an individual patient basis

Pathologic Complete Response (pCR) Primary goal of NACT in TNBC and HER2+ BC

- Definition: No invasive cancer in the breast or axillary lymph nodes (ypT0,ypN0)
 - Residual DCIS does not influence the definition
 - Caution: Multiple other definitions used in earlier studies
- Prognostic for long term outcome at the individual patient level



Association of pCR on EFS and OS




Pennington Cancer Institute


What the CTNeoBC meta-analysis tells us about pCR

- pCR is a reliable prognostic marker
 - Individual patients with pCR have superior outcomes
- Definition matters: Eradication of invasive cancer from breast + nodes sufficient
 - Residual DCIS not prognostically important
- Subtype matters: Magnitude of difference in outcome between pCR+ and no pCR differs between subgroups

Cortazar et al, Lancet 2014; 384: 164-72



Response to NACT is heterogeneous




Traditional staging by TNM after NACT (yp T, yp N) doesn't represent prognosis well

Can we do better to sort patients who need additional therapy?



Residual Cancer Burden (RCB) as an alternative neoadjuvant biomarker

Method to quantify residual disease ranging from pathological complete response to extensive residual disease.




Highly reproducible:

- Concordance correlation coefficient = 0.931 (0.908–0.949).
- Overall accuracy = 0.989.
- Kappa coefficient for overall agreement = 0.583 (0.539–0.626).

Symmans et al. J Clin Oncol. 2007; Peintinger, Modern Pathology, 2015

RCB in 5161 patients: Prognosis varies by subtype



Pennington Cancer Institute

Yau, C et al. Lancet Onc 2022

Neoadjuvant Chemotherapy for TNBC

No targeted therapies available


- Anthracycline and Taxanes give best response
- Dose density
- Addition of carboplatin improves pCR and EFS

Recent advances

 TNBC is more immune-activated (increased TILs); implications for Immune therapy




KEYNOTE-522 Study Design (NCT03036488)



Neoadjuvant phase: starts from the first neoadjuvant treatment and ends after definitive surgery (post treatment included) **Adjuvant phase:** starts from the first adjuvant treatment and includes radiation therapy as indicated (post treatment included)

Schmid P, ESMO Virtual Plenary 2021

KEYNOTE-522: EFS at IA4




1. Schmid P, et al. Presented at ESMO Virtual Plenaries; 15–16 July 2021. Abstract VP7-2021. 2. Schmid P et al. New Engl J Med 2022 3. Pembrolizumab ODAC Briefing Document For Public Release. BLA 125514 Supplement-089. February 2021.

San Antonio Breast Cancer Symposium®, December 5-9, 2023

LONG TERM FOLLOWUP OF KN-522

EFS at IA6 by Disease Stage




Data cutoff date of March 23, 2023.

This presentation is the intellectual property of the author/presenter. Contact them at p.schmid@qmul.ac.uk for permission to reprint and/or distribute.

LONG TERM FOLLOWUP OF KN-522

EFS at IA6 by Disease Stage in Patients With and Without pCR



Data cutoff date of March 23, 2023.

This presentation is the intellectual property of the author/presenter. Contact them at <u>p.schmid@qmul.ac.uk</u> for permission to reprint and/or distribute.

Neoadjuvant Therapy for HER2+ disease

- Anthracycline + taxane based chemotherapy
- Trastuzumab added significantly
- Pertuzumab added benefit (pCR and EFS) to chemo + trastuzumab
- Non-anthracycline regimens give equal results to anthracycline with less cardiac toxicity




Neoadjuvant Non-Anthracycline

Taxane/Carbo-Based Regimens with trastuzumab +/- pertuzumab (N=895)

Regimen/ Study	N	tpCR
TCH x 6 TRIO B07/Hurvitz, et al. Nature Comm 2020	34	47%
TCHP x 6 TRYPHAENA/Schneeweiss, et al. Ann Oncol 2013	77	64 %
TCHP x 6 KRISTINE-TRIO-021/Hurvitz, et al. Lancet Oncol 2018	221	56%
TCHP x 4 (in HR+ only) NSABP B52/Rimawi, et al. Cancer Res 2016, SABCS S3-06	155	41% HR+ only
Paclitaxel/Carbo/Trastuzumab/Pertuzumab x 9 TRAIN-2/van Ramshorst et al. Lancet Oncol 2018	206	68%
TCH x 6 neoCARH/Gao, et al. ASCO 2020 Abs 585	131	56%
TCHP x 6 PHERGAIN/Perez-Garcia, et al. Lancet 2021	71	58%

KATHERINE 2nd OS interim analysis; median follow-up 8.4 years (101 months)



Significant reduction in risk of death by 34% with T-DM1

Neoadjuvant therapy for HR+HER2- disease


- Grade 3
- Young (<40)
- At least T2N1
- Typically dose dense AC-T chemotherapy
- Some patients are candidates for Neoadjuvant endocrine therapy

Adjuvant therapy after neoadjuvant therapy: Varies by response to therapy For non-pCR patients:

- HER2+: Additional anti-HER2 therapy (T-DM1)
- TNBC: Continue Pembro if by KN-522 +/-capecitabine
- HR+HER2-: Endocrine therapy + abemaciclib
- BRCA 1/2+: Olaparib







Neoadjuvant chemo-immunotherapy for TNBC Treatment optimization

- Treatment de-escalation: Do all patients need 4-drug poly-chemotherapy when immunotherapy is part of neoadjuvant systemic therapy?
 - I-SPY 2.2: Ongoing arms assessing novel agents/combinations to allow early de-escalation
 - Chemotherapy de-escalation: S2212 (SCARLET)
- Treatment escalation: Early identification of patients unlikely to achieve optimal response with standard neoadjuvant treatment
 - Tissue, Imaging +/- Machine learning/AI, Circulating biomarkers (ctDNA)
 - Neoadjuvant testing of novel more effective therapies
- Preferential immunotherapy response biomarkers


Shorter anthracycline-free Chemoimmunotherapy Adapted to pathological Response in Early TNBC (SCARLET)

Randomized non-inferiority trial

Olaparib per MD discretion in aBRCA allowed

No Further Adjuvant chemotherapy

Hypothesis: In patients with early stage TNBC, carboplatin-<u>taxane</u> chemoimmunotherapy is non-inferior to <u>taxane</u>platinum-anthracycline-based chemoimmunotherapy





"True optimization is the revolutionary contribution of modern research to decision processes." George Dantzig



#ASCO23



Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Metastatic Breast Cancer

nig

Incidence of Metastatic Breast Cancer

- 3%-6% of patients have MBC at the initial diagnosis of breast cancer in US
- 20% of patients with stage I to III at diagnosis will develop MBC (without systemic therapy)

Goals of Systemic Therapy in MBC


- Improve survival
- Delay time to disease progression
- Palliate symptoms
- Minimize toxicity of therapy

Individualized Management of MBC

Tumor biology (Subtype)	 Hormone receptor status (protein) HER2 status (protein or gene)
Tumor aggressiveness	 Timing of relapse since primary diagnosis Location of mets (visceral vs non-visceral) Extent of metastatic spread (oligo vs polymets)
Prior adjuvant therapy	 Endocrine, biologic or chemotherapy Combined treatments
Local and systemic approaches	 Oligometastatic disease Surgery, radiofrequency ablation, stereotactic radiotherapy
Patient	 Preferences – scheduling issues Symptoms Co-morbidities

Individualize treatment to patient and tumor biology


What Is the Optimal Therapy for a Patient With Advanced HR+/HER2- Breast Cancer?



Brufsky. Oncologist. 2018;23:528. AlFakeeh. Curr Oncol. 2018;25:S18. Di Cosimo. Nat Rev Clin Oncol. 2010;7:139.

- Endocrine backbone: Als or SERD (Fulvestrant)
 + OFS for premenopausal
- First line therapy-Endocrine Based
 - Combination endocrine and CDK 4/6 inhibitor as first line therapy for most
 - Premenopausal patients can receive above with OFS
- Second line therapy-Endocrine Based
 - Exemestane + Everolimus
 - Fulvestrant + Everolimus
 - IF PIK3CA mutated, Alpelisib + Fulvestrant
 - If PIK3CA, AKT or PTEN mutated, Capivasertib + Fulvestrant

Trials of Frontline AI ± CDK4/6 Inhibitor in Advanced Postmenopausal Breast Cancer: PFS




Mo

1. Finn. NEJM. 2016;375:1925. 2. Hortobagyi. Ann Oncol. 2018;29:1541. 3. Goetz. JCO. 2017;35:3638.

*ORR for patients with measurable disease.

HR+HER2- MBC: Continue endocrine/targeted therapies until fully resistant



Current NCCN guidelines for HR+HER2- MBC

SYSTEMIC THERAPY REGIMENS FOR RECURRENT UNRESECTABLE (LOCAL OR REGIONAL) OR STAGE IV (M1) DISEASE^a

HR-Positive and HER2-Negative with Visceral Crisis [†] or Endocrine Refractory			
Setting	Subtype/Biomarker	Regimen	
First Line	No germline BRCA1/2 mutation ^b	Systemic chemotherapy BINV-Q (5)	
	Germline BRCA1/2 mutation ^b	PARPi (olaparib, talazoparib) ^c (Category 1, preferred)	
Second Line HER2 IHC 1+ or 2+/ISH negative ^d		Fam-trastuzumab deruxtecan-nxki ^e (Category 1, preferred)	
	Not a candidate for fam-trastuzumab	Sacituzumab govitecan ^f (Category 1, preferred)	
	deruxtecan-nxki	Systemic chemotherapy BINV-Q (5)	
Third Line and beyond	Any	Systemic chemotherapy BINV-Q (5)	
Biomarker positive (ie, MSI-H, NTRK, RET, TMB-H)		Targeted agents BINV-Q (6)	

[†] According to the 5th ESO-ESMO international consensus guidelines (Cardoso F, et al. Ann Oncol 2020;31:1623-1649) for advanced breast cancer visceral crisis is defined as: "severe organ dysfunction, as assessed by signs and symptoms, laboratory studies and rapid progression of disease. Visceral crisis is not the mere presence of visceral metastases but implies important organ compromise leading to a clinical indication for the most rapidly efficacious therapy."

NCCN Guidelines® Breast Cancer Version 2.2024

Current NCCN guidelines for TN MBC

HR-Negative and HER2-Negative (Triple-Negative Breast Cancer; TNBC)				
Setting	Subtype/Biomarker	Regimen		
First Line	PD-L1 CPS ≥10 ^g regardless of germline BRCA mutation status ^b	Pembrolizumab + chemotherapy (albumin-bound paclitaxel, paclitaxel, or gemcitabine and carboplatin) ^h (Category 1, preferred)		
	PD-L1 CPS <10 ^g and no germline BRCA1/2 mutation ^b	Systemic chemotherapy BINV-Q (5)		
	PD-L1 CPS <10 ^g and germline BRCA1/2 mutation ^b	 PARPi (olaparib, talazoparib) (Category 1, preferred) Platinum (cisplatin or carboplatin) (Category 1, preferred) 		
Line Any No	Germline BRCA1/2 mutation ^b	PARPi (olaparib, talazoparib) (Category 1, preferred)		
	A	Sacituzumab govitecan ⁱ (Category 1, preferred)		
	Any	Systemic chemotherapy BINV-Q (5)		
	No germline BRCA1/2 mutation ^b and HER2 IHC 1+ or 2+/ISH negative ^d	Fam-trastuzumab deruxtecan-nxki ^e (Category 1, preferred)		
Third Line and beyond	Biomarker positive (ie, MSI-H, NTRK, RET, TMB-H)	Targeted agents BINV-Q (6)		
	Any	Systemic chemotherapy BINV-Q (5)		

NCCN Guidelines® Breast Cancer Version 2.2024

Immunotherapy in MBC: Currently restricted to TNBC with PD-L1 expression

1st line MBC TNBC (ER-PR-HER2-) No prior IO Chemotherapy +/- Pembrolizumab All PD-L1 levels eligible 40% of patients have PD-L1 CPS score of >/= 10

Overall Survival: PD-L1 CPS ≥10




^aPrespecified *P* value boundary of 0.0113 met. Hazard ratio (CI) analyzed based on a Cox regression model with treatment as a covariate stratified by the randomization stratification factors. Data cutoff: June 15, 2021.

PD-L1 negative patients receive chemotherapy and antibody drug conjugates (ADCs)


Systemic Therapy Options For HER2+Stage IV Disease NCCN Guidelines

First-Line Regimens	Second-Line Regimens			her Recommended mens
 Trastuzumab + Pertuzumab + docetaxel (1) Trastuzumab + Pertuzumab + paclitaxel 	Trastuzumab Deruxtecan	•	Tucatinib + trastuzumab + capecitabine (1) ^{ab} Trastuzumab emtansine	 Lapatinib + capecitabine Trastuzumab + lapatinib (without cytotoxic therapy)
Anti-HER2 therapy ^a Regimen may be used as a third- or fourth-line op therapy and beyond is not known. ^b Tucatinib + trastuzumab + capecitabine is preferre CNS progression on ado-trastuzumab emtansine.	tion; the optimal sequence for third-line		Trastuzumab + paclitaxel ± carboplatin Trastuzumab + docetaxel Trastuzumab + vinorelbine Trastuzumab + capecitabine	 Trastuzumab + other agents Neratinib + capecitabine Additional targeted therapy

ADC: Structure and Characteristics




ADCs: Development and approval




Chau el at. Lancet 2019; 394(10200) Fu et al. Signal Transduction and Targeted Therapy 2022; 7(93)


T-DM1 versus T-DXd ADC characteristics



T-DM1 ¹⁻³	ADC Attributes	T-DXd ^{2–5*}
Trastuzumab	Antibody	Trastuzumab
Emtansine	Payload	Deruxtecan
Anti-microtubule	Payload MoA	Topoisomerase I inhibitor
~3.5:1	Drug-to-antibody ratio	~8:1
No	Tumor-selective cleavable linker?	Yes
No	Evidence of bystander anti-tumor effect?	Yes
		5 1




DESTINY-B03: Updated Primary Endpoint –PFS by BICR



Hurvitz S, et al SABCS 2022

ASCENT: A Phase 3 Study of Sacituzumab Govitecan in mTNBC



Median OS-mo (95% CI)

HR (95% CI), P-value

12.1 (10.7-14.0)

0.48 (0.38-0.59), P<0.0001

6.7 (5.8-7.7)

BICR Analysis	SG (n=235)	TPC (n=233)		
No. of events	166	150		
Median PFS—mo (95% CI)	5.6 (4.3-6.3)	1.7 (1.5-2.6)		
HR (95% CI), <i>P</i> -value	0.41 (0.32-0.52), <i>P</i> <0.0001			

DESTINY-Breast04: First Randomized Phase 3 Study of T-DXd for HER2-low mBC


An open-label, multicenter study (NCT03734029)

Patients^a

- HER2-low (IHC 1+ vs IHC 2+/ISH-), unresectable, and/or mBC treated with 1-2 prior lines of chemotherapy in the metastatic setting
- HR+ disease considered
 endocrine refractory

Stratification factors

- Centrally assessed HER2 status^d (IHC 1+ vs IHC 2+/ISH–)
- 1 versus 2 prior lines of chemotherapy
- HR+ (with vs without prior treatment with CDK4/6 inhibitor) versus HR-



Primary endpoint


• PFS by BICR (HR+)

Key secondary endpoints^b

- PFS by BICR (all patients)
- OS (HR+ and all patients)

ASCO/CAP, American Society of Clinical Oncology/College of American Pathologists; BICR, blinded independent central review; CDK, cyclin-dependent kinase; DOR, duration of response; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IHC, immunohistochemistry; ISH, in situ hybridization; mBC, metastatic breast cancer; OS, overall survival; PFS, progression-free survival; Q3W, every 3 weeks; R, randomization; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice. ^aIf patients had HR+mBC, prior endocrine therapy was required. ^bOther secondary endpoints included ORR (BICR and investigator), DOR (BICR), PFS (investigator), and safety; efficacy in the HR-cohort was an exploratory endpoint. ^cTPC was administered accordingly to the label. ^dPerformed on adequate archived or recent tumor biopsy per ASCO/CAP guidelines using the VENTANA HER2/neu (4B5) investigational use only [IUO] Assay system.

T-DXd vs. chemo after 1st line HER2-low



TPC (n = 184): 184 166 119 93 90 73 60 51 45 34 32 29 26 22 15 13 9 5 3 4

TPC (n = 184) 28 120 114 108 105 97 88 77 61 50 42 32 28

ADCs have transformed chemotherapy delivery for MBC- and will continue to:

- Moving into first line
- Multiple new agents and payloads
- Bispecifics



Multimodality Therapy of MBC

- Bone targeted agents
 - Adjunct to cancer directed therapy
 - Reduce skeletal related events (fractures, need for radiation and surgery, pain)
 - Bisphosphonates (zoledronic acid) or RANK-ligand inhibitor (denosumab)
 - Typically initiated monthly
- Radiation
 - To painful/symptomatic lesions
- Surgery
 - Do not do mastectomy in de novo stage IV patients
 - Selected use in other circumstances



Outcomes for MBC by subtype: 2024

- HER2+ Disease: Median OS >7 years
- HR+/HER2- Disease: Median OS >6 years
- TNBC: Median OS 2-2.5 years

MBC is now a chronic disease: Ongoing efforts to prolong survival while reducing toxicity so patients can enjoy as normal a life as possible



